ABOUT HEMGENIX

Number of eligible patients: CDEC mentioned the uncertainty in the amount of individuals with moderately significant to significant hemophilia B in Canada qualified for etranacogene dezaparvovec. Clinical professionals consulted by CADTH indicated that some sufferers who're classified as getting mild or average sickness may have a intense bleeding